Literature DB >> 3189047

The topical anti-inflammatory and analgesic properties of bromfenac in rodents.

J C Nolan1, L E Wagner, C E Gathright, D J Stephens, L F Sancilio.   

Abstract

Bromfenac [2-amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt sesquihydrate] is an anti-inflammatory/analgesic agent that possesses potent topical activity in rats, guinea pigs, and mice. In rat models of acute (carrageenan paw edema) and chronic (adjuvant arthritis) inflammation, preparations of bromfenac at concentrations as low as 0.01-0.32% (0.01-0.32 mg bromfenac) produced significant anti-inflammatory activity when applied to the injected paw or to the backs of rats. In the acute paw edema test, topical bromfenac was more potent than indomethacin or hydrocortisone and about as active as triamcinolone acetonide. Bromfenac, at concentrations of 0.1-0.32%, showed topical analgesic activity in the acetylcholine-induced abdominal constriction test in mice. In this test, bromfenac was more potent than indomethacin (24.9X), more potent than ketoprofen (approximately 14.9X), and superior to piroxicam. In the guinea pig UV-erythema test, bromfenac was active (26.1X indomethacin) when applied to the UV-exposed site, but not when applied away from the site. The results suggest that bromfenac has activity topically because of a local and a systemic effect. Test results obtained with a long (4-7 hr) pretreatment time (paw edema, adjuvant arthritis, abdominal constriction) are due in great part to a systemic effect of topically applied bromfenac, while the UV-erythema test (1-hr treatment time) clearly indicates a local effect.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3189047     DOI: 10.1007/bf01969098

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  18 in total

1.  The effect of systemically and topically applied drugs on ultraviolet-induced erythema in the rat.

Authors:  E Law; A J Lewis
Journal:  Br J Pharmacol       Date:  1977-04       Impact factor: 8.739

2.  AHR-5850: a potent anti-inflammatory compound.

Authors:  L F Sancilio; D L Reese; S Cheung; R S Alphin
Journal:  Agents Actions       Date:  1977-03

3.  Local anti-inflammatory properties of etoclofene. A new fenamate derivative.

Authors:  G B Fregnan; A L Torsello; S Brunet
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

4.  Adjuvant-induced arthritis in rats. II. Drug effects on physiologic, biochemical and immunologic parameters.

Authors:  D T Walz; M J DiMartino; A Misher
Journal:  J Pharmacol Exp Ther       Date:  1971-07       Impact factor: 4.030

5.  Anti-inflammatory activity of orpanoxin administered orally and topically to rodents.

Authors:  R R Brooks; K R Bonk; G E Decker; K E Miller
Journal:  Agents Actions       Date:  1985-07

6.  Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.

Authors:  D A Walsh; H W Moran; D A Shamblee; I M Uwaydah; W J Welstead; L F Sancilio; W N Dannenburg
Journal:  J Med Chem       Date:  1984-11       Impact factor: 7.446

7.  The topical anti-inflammatory effects of piroxicam in rodents.

Authors:  D L Larson; J G Lombardino
Journal:  Agents Actions       Date:  1980-06

8.  Assessment of topical anti-inflammatory activity in rats with cantharidin-induced inflammation.

Authors:  A Boris; J F Hurley
Journal:  J Invest Dermatol       Date:  1977-03       Impact factor: 8.551

9.  BRL 20459, a novel topically active non-steroidal anti-inflammatory drug.

Authors:  A P Green; F R Mangan; M J Thomson; K E Randall; E A Boyle
Journal:  J Pharm Pharmacol       Date:  1984-05       Impact factor: 3.765

10.  Concentration-dependent enhancement of 1-dodecylazacycloheptan-2-one on the percutaneous penetration kinetics of triamcinolone acetonide.

Authors:  D S Chow; I Kaka; T I Wang
Journal:  J Pharm Sci       Date:  1984-12       Impact factor: 3.534

View more
  1 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of bromfenac.

Authors:  N M Skjodt; N M Davies
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.